Skip to content
ClinCalc Pro
Menu
Cardiology Infectious Disease

2023 Duke-ISCVID Criteria for Infective Endocarditis

Updated 2023 Duke criteria incorporating CT, PET-CT, and MRI findings for IE diagnosis. Classification: Definite, Possible, or Rejected.

≥2 positive blood cultures with typical organisms (Strep viridans, Strep bovis, HACEK, S. aureus, Enterococcus without primary focus) OR persistently positive cultures > 12h apart OR ≥3 of ≥4 positive cultures

Vegetation, abscess, pseudoaneurysm, fistula, valvular perforation, new valvular regurgitation, new prosthetic dehiscence on echo; OR CT/PET-CT showing abnormal activity around prosthetic valve or vascular graft

Prosthetic valve, prior IE, congenital heart disease, other predisposing condition, or IVDU

Major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial haemorrhage, conjunctival haemorrhage, Janeway lesions

Glomerulonephritis, Osler nodes, Roth spots, positive rheumatoid factor

Positive blood culture not meeting major criteria, OR serological evidence of active infection with organism consistent with IE

Score interpretation

Rejected 0–9

Insufficient criteria for IE. Alternative diagnosis more likely, OR symptoms resolve with ≤4 days of antibiotics.

→ Reassess for alternative diagnoses. Repeat blood cultures if clinical suspicion persists.

Possible Infective Endocarditis 10–19

1 major + 1 minor criteria, OR ≥3 minor criteria. Possible IE.

→ Continue workup. Repeat blood cultures. Echocardiography (TTE then TOE). Specialist ID/Cardiology review.

Definite Infective Endocarditis 20–100

2 major OR 1 major + 3 minor OR ≥5 minor criteria. Definite IE. Also definite if pathological criteria met.

→ Commence IV antibiotics per local protocol. Cardiothoracic surgery consultation. IE MDT team activation.

Interpretation bands for the Duke-ISCVID 2023. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

The Duke-ISCVID 2023 is covered in detail — with RCEM/NICE evidence base, indications and pitfalls — in the following exam-focused pathways on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.